Preparing Ibrutinib analysis for the next wave of market access

[Article Title]

As Ibrutinib moves closer to broader availability, laboratories are already laying the groundwork for future demand. Without an established monograph, reliable methods are essential to ensure readiness. This technical note introduces a robust approach using a thermally modified Luna Omega C18 column for clear impurity separation and accurate assay quantification. Designed with tomorrow in mind, this method helps labs build confidence and capability ahead of anticipated market expansion.

Download the Document

    * denotes a required field

    Please fill out the information below. If you are already registered, and this information will be filled out for you.

  • Please enter your first and last name.

  • Please enter the name of the company or institution you work at.

  • Please enter your mailing address.

  • Please enter the e-mail address you would like to be contacted at.

  • Please enter the phone number you would like to be contacted at.

    • By submitting this form, you consent to American Pharmaceutical Review storing your email address and contact information and transmitting your contact information to the content sponsor. You may request to be removed at any time.